

VIRUSES

Biology Applications Control

David R. Harper

| | | | |
|---|-----------|--|-----------|
| Chapter 1 Virus Structure and Infection | 1 | 2.2 VIRUS MORPHOLOGY | 26 |
| Introduction | 1 | 2.3 VIRAL CLASSIFICATION BY GENOME TYPE | 26 |
| 1.1 WHAT IS A VIRUS? | 2 | 2.4 SUPERVIRUSES AND SUB-VIRUSES | 30 |
| What makes a virus? | 4 | Supervirus | 31 |
| 1.2 VIRUS STRUCTURE AND MORPHOLOGY | 5 | Sub-viral infections | 31 |
| Capsids | 5 | Satellite viruses | 31 |
| Capsid symmetry | 7 | Virusoids | 32 |
| Virus envelopes | 8 | Viroids | 32 |
| 1.3 THE VIRAL GENOME | 9 | Deltavirus | 33 |
| Genome size and virus structure | 9 | Replication-defective viruses | 33 |
| Genome size and infection | 9 | Mobile genetic elements | 34 |
| Making the most of a limited genome | 10 | Endogenous viruses | 34 |
| Genome type and virus replication | 12 | Prions | 34 |
| Mutation in the HIV genome | 13 | The prion hypothesis | 35 |
| 1.4 THE EFFECTS OF VIRUS INFECTION | 14 | From cows to man | 36 |
| 1.5 TYPES OF VIRUS INFECTION | 15 | 2.5 WHERE DO VIRUSES COME FROM? | 37 |
| Lytic infections | 16 | KEY CONCEPTS | 39 |
| Persistent or chronic infections | 16 | DEPTH OF UNDERSTANDING QUESTIONS | 39 |
| Latent infections | 16 | FURTHER READING | 39 |
| Cellular transformation | 17 | INTERNET RESOURCES | 40 |
| KEY CONCEPTS | 19 | Chapter 3 Virus Replication | 41 |
| DEPTH OF UNDERSTANDING QUESTIONS | 19 | Introduction | 41 |
| FURTHER READING | 19 | 3.1 ATTACHMENT AND ENTRY | 42 |
| INTERNET RESOURCES | 20 | Cellular receptors for viruses | 43 |
| Chapter 2 Virus Classification and Evolution | 21 | Virus entry | 45 |
| Introduction | 21 | 3.2 REPLICATION | 47 |
| 2.1 VIRUS CLASSIFICATION | 22 | Sites of virus replication | 47 |
| | | Entry into the nucleus | 48 |
| | | Synthesis of viral proteins | 48 |

| | |
|--|----|
| 3.3 SYNTHESIS OF VIRAL GENOMES | 50 |
| DNA synthesis | 50 |
| Viruses with double-stranded (ds) DNA genomes | 51 |
| Viruses with single-stranded (ss) DNA genomes | 52 |
| DNA viruses that use an RNA intermediate | 53 |
| RNA synthesis | 55 |
| Viruses with double-stranded (ds) RNA genomes | 56 |
| Viruses with positive-strand ssRNA genomes | 56 |
| Viruses with negative-strand ssRNA genomes | 58 |
| ssRNA (positive-sense) viruses that use a DNA intermediate | 59 |
| 3.4 VIRAL REGULATION OF CELLULAR ACTIVITIES | 60 |
| 3.5 VIRUS ASSEMBLY AND RELEASE | 61 |
| KEY CONCEPTS | 63 |
| DEPTH OF UNDERSTANDING QUESTIONS | 64 |
| FURTHER READING | 64 |
| INTERNET RESOURCES | 64 |

Chapter 4 Immune Response and Evasion 65

| | |
|--|----|
| Introduction | 65 |
| 4.1 THE INNATE IMMUNE RESPONSE | 67 |
| Recognition: Toll-like receptors | 67 |
| Signaling: cytokines and interferons | 67 |
| Phagocytosis | 71 |
| NK cells | 71 |
| Innate-like lymphocytes | 72 |
| The complement system | 72 |
| 4.2 THE SEROLOGICAL IMMUNE RESPONSE | 73 |
| Antibody structure | 73 |
| The five types of immunoglobulin | 74 |
| The B-cell receptor and the proliferative response | 75 |
| Generation of antigenic diversity | 76 |
| B-cell memory | 78 |
| B-cell epitopes | 78 |
| The effects of antibody binding | 79 |
| The significance of the serological response | 79 |
| 4.3 THE CELL-MEDIATED ADAPTIVE IMMUNE RESPONSE | 80 |
| T-cell activation | 83 |
| The MHC-I pathway: cytotoxic T cells | 84 |
| The MHC-II pathway: helper T cells | 84 |
| Th1 and Th2 | 85 |
| T cells: suppression and memory | 85 |

| | |
|---|----|
| 4.4 COMPARTMENTALIZATION OF THE IMMUNE RESPONSE | 87 |
| Mucosal immunity | 87 |
| 4.5 APOPTOSIS | 88 |
| 4.6 EVASION OF IMMUNE SURVEILLANCE BY VIRUSES | 89 |
| Active immune evasion | 89 |
| HIV and the immune system | 90 |
| Passive immune evasion | 90 |
| A combined effect | 91 |
| 4.7 HOST GENETIC FACTORS | 91 |
| 4.8 VIRAL ONCOGENESIS | 92 |
| The role of cellular tumor suppressor genes | 93 |
| Viral oncogenes | 93 |
| KEY CONCEPTS | 95 |
| DEPTH OF UNDERSTANDING QUESTIONS | 96 |
| FURTHER READING | 96 |
| INTERNET RESOURCES | 96 |

Chapter 5 Vaccines and Vaccination 97

| | |
|---|-----|
| Introduction | 97 |
| 5.1 THE ORIGINS OF VACCINATION | 98 |
| Variolation | 98 |
| Vaccination | 99 |
| 5.2 CURRENT VACCINES | 100 |
| Types of vaccine | 100 |
| Live vaccines | 101 |
| An example: oral polio vaccine | 102 |
| Defined attenuation | 104 |
| Inactivated vaccines | 104 |
| Subunit vaccines | 105 |
| Cloned subunit vaccines | 105 |
| HIV: the center of attention | 106 |
| 5.3 ADJUVANTS | 107 |
| The components of an adjuvant | 109 |
| Liposomes and cochleates | 109 |
| T cells and adjuvants | 109 |
| 5.4 APPROACHES TO VACCINE DEVELOPMENT | 110 |
| Viral vectors | 111 |
| Replication-deficient viruses: gene vectors | 114 |
| Nucleic acid vaccination | 114 |
| 5.5 TAILORING OF THE IMMUNE RESPONSE TO VACCINATION | 115 |

| | | | |
|--|------------|---|------------|
| 5.6 ALTERNATIVE DELIVERY SYSTEMS | 116 | Oligonucleotides | 146 |
| Oral administration of vaccines | 116 | Ribozymes | 148 |
| Mucosal immunity | 116 | RNA interference: siRNAs and miRNAs | 148 |
| Slow release | 117 | Approved drugs | 149 |
| 5.7 THERAPEUTIC VACCINATION | 117 | 6.6 IMMUNOTHERAPIES | 149 |
| 5.8 EPITOPE STRUCTURE IN VACCINE DEVELOPMENT | 118 | Production of specific antibodies | 149 |
| Identification of epitopes | 118 | Monoclonal antibodies | 149 |
| 5.9 SOCIAL OPPOSITION TO VACCINATION | 119 | Humanization | 151 |
| Something in the mixture | 120 | Human monoclonal antibodies | 152 |
| The bottom line | 120 | Recombinant antibodies | 153 |
| Polio vaccine conspiracy theories | 121 | Micro-antibodies | 153 |
| One small study | 121 | Targeting using monoclonal antibodies | 153 |
| 5.10 PRACTICAL ISSUES AND OUTCOMES OF VACCINATION | 122 | Interferons | 154 |
| The eradication of a disease | 122 | 6.7 RESISTANCE TO ANTIVIRAL DRUGS | 155 |
| Risk and benefit | 124 | Resistance to anti-HIV drugs | 155 |
| Vaccination in infancy | 125 | Resistance to anti-herpesvirus drugs | 156 |
| Production issues | 126 | Minimizing resistance | 156 |
| Endogenous growth | 126 | 6.8 COMBINATION THERAPY | 157 |
| The wrong type of immunity | 127 | Highly active anti-retroviral therapy | 157 |
| Direct effects | 127 | Antagonism, addition, and synergy | 158 |
| Monitoring safety | 128 | 6.9 LIMITATIONS OF ANTIVIRAL DRUGS | 159 |
| Future potential | 128 | Treating the symptoms | 160 |
| KEY CONCEPTS | 128 | CONCLUSIONS | 161 |
| DEPTH OF UNDERSTANDING QUESTIONS | 129 | KEY CONCEPTS | 161 |
| FURTHER READING | 129 | DEPTH OF UNDERSTANDING QUESTIONS | 162 |
| INTERNET RESOURCES | 129 | FURTHER READING | 162 |
| | | INTERNET RESOURCES | 162 |
| Chapter 6 Antiviral Drugs | 131 | Chapter 7 Beneficial Use of Viruses | 163 |
| Introduction | 131 | Introduction | 163 |
| 6.1 EARLY ANTIVIRAL DRUG DEVELOPMENT | 132 | 7.1 GENE THERAPY | 164 |
| 6.2 TOXICITY | 132 | Virus vector systems | 165 |
| 6.3 DEVELOPMENT OF ANTIVIRAL DRUGS | 133 | Complications | 165 |
| The development pathway: preclinical, clinical, and beyond | 134 | Problems | 167 |
| High-throughput screening | 135 | Where are we now? | 168 |
| Rational design | 136 | 7.2 CANCER PREVENTION AND CONTROL | 168 |
| Development from existing drugs | 138 | Vaccines | 168 |
| The cost of drug development | 139 | Virotherapy | 169 |
| 6.4 CURRENT ANTIVIRAL DRUGS | 140 | Virus-directed enzyme prodrug therapy (VDEPT) | 171 |
| Nucleoside analogs: understanding the mechanism | 144 | 7.3 BIOLOGICAL PEST CONTROL | 172 |
| 6.5 NUCLEIC ACID-BASED APPROACHES | 146 | Viruses to control insect pests | 174 |
| | | Viruses to control rabbits | 175 |
| | | Resistance | 176 |

| | | | |
|--|------------|--|------------|
| Integrated pest management | 177 | KEY CONCEPTS | 214 |
| 7.4 BACTERIOPHAGE THERAPY | 177 | DEPTH OF UNDERSTANDING QUESTIONS | 214 |
| Bacteriophages | 177 | FURTHER READING | 214 |
| Bacteriophages as therapeutic agents | 179 | INTERNET RESOURCES | 215 |
| The antibiotic age | 180 | | |
| A renewal of interest in bacteriophages | 181 | Chapter 9 Viruses, Vectors, and Genomics | 217 |
| Into the clinic | 183 | Introduction | 217 |
| KEY CONCEPTS | 183 | 9.1 GENETIC MANIPULATION | 218 |
| DEPTH OF UNDERSTANDING QUESTIONS | 184 | Cloning | 219 |
| FURTHER READING | 184 | Expression | 220 |
| INTERNET RESOURCES | 184 | Post-translational processing | 221 |
| | | Virus-based systems for expression in eukaryotic cells | 223 |
| Chapter 8 Emergence, Spread, and Extinction | 185 | Viral vectors | 226 |
| Introduction | 185 | 9.2 SEQUENCING | 226 |
| 8.1 SURVEILLANCE | 186 | Metagenomics | 228 |
| Too little: hantavirus pulmonary syndrome | 187 | Virus genome sequencing | 229 |
| Too much: swine flu | 187 | Junk or not junk? | 229 |
| Influenza: from surveillance to pandemic | 188 | 9.3 SYNTHESIS AND AMPLIFICATION | 230 |
| The return of swine flu | 188 | 9.4 PERSONALIZED MEDICINE | 231 |
| The swine flu controversy | 190 | KEY CONCEPTS | 231 |
| The role of surveillance | 190 | DEPTH OF UNDERSTANDING QUESTIONS | 232 |
| 8.2 EMERGENCE | 192 | FURTHER READING | 232 |
| Zoonosis | 192 | INTERNET RESOURCES | 232 |
| Sin Nombre and Hantaan viruses | 194 | | |
| Ebola and Marburg | 196 | Chapter 10 Culture, Detection, and Diagnosis | 233 |
| HIV | 196 | Introduction | 233 |
| Severity of zoonotic infections | 197 | 10.1 ELECTRON MICROSCOPY | 234 |
| Zoonosis through medical procedures | 197 | Diagnostic electron microscopy | 234 |
| Geographical contact | 199 | 10.2 CYTOLOGY | 236 |
| Mutation | 200 | 10.3 VIRUS CULTURE | 238 |
| Recombination | 201 | Containment | 239 |
| Genetic manipulation | 202 | Growing and counting viruses | 240 |
| Identification | 202 | Diagnostic virus culture | 240 |
| Reappearance | 203 | 10.4 SEROLOGICAL AND IMMUNOLOGICAL ASSAYS | 243 |
| Deliberate release | 204 | 10.5 NUCLEIC ACID DETECTION AND AMPLIFICATION | 243 |
| Accidental release | 206 | Hybridization | 244 |
| Factors favoring the emergence of a disease | 206 | Nucleic acid amplification | 246 |
| 8.3 SPREAD | 208 | The polymerase chain reaction | 247 |
| Modes of transmission | 208 | | |
| Transmission by arthropods | 209 | | |
| Sylvatic and urban cycles | 210 | | |
| Control of arbovirus infections | 211 | | |
| 8.4 EXTINCTION | 212 | | |

| | |
|--|----------------|
| Alternative amplification-based detection systems | 248 |
| Detection of amplified nucleic acids | 249 |
| Problems of amplification-based nucleic acid detection systems | 250 |
| Microarrays | 252 |
| High-throughput sequencing | 253 |
| 10.6 FUTURE DEVELOPMENTS IN DIAGNOSTIC VIROLOGY | 253 |
| KEY CONCEPTS | 254 |
| DEPTH OF UNDERSTANDING QUESTIONS | 254 |
| FURTHER READING | 254 |
| INTERNET RESOURCES | 255 |
| Appendix I Virus Replication Strategies | 257 |
| Appendix II Current Antiviral Drugs | 283 |
| Glossary | 299 |
| Index | 306 |